Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Get your questions posted!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(112)
•••
Comment by prophetoffactzon Jun 20, 2022 3:05pm
158 Views
Post# 34769444

RE:RE:Get your questions posted!

RE:RE:Get your questions posted!Interesting that BTI still appears to be 2-3 years from filing an IND for xB3 and that given BTI will be doing a small staged financing on the way to $6 million it doesn't appear as though there is much if any significant money coming in from partner mllestones or licensing of xB3 any time soon despite the timelines since the deals were announced. Difficult market conditions were mentioned. After a decade in development BTI's lead program is suddenly a program that doesn't require xB3 as it can get over the blood brain barrier by itself.

Seems like right now the play is if BTI and Ladenberg can talk the stock up ahead of a staged financing despite market conditions.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities